These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1102 related items for PubMed ID: 25439533

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J, Aparicio LS, Waisman GD.
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
    Wong J.
    Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
    [Abstract] [Full Text] [Related]

  • 25. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G.
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A, Saruta T, Funder JW.
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R, Palmer BF.
    Am J Nephrol; 2008 Apr; 28(3):372-80. PubMed ID: 18073461
    [Abstract] [Full Text] [Related]

  • 31. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M, Simioni N, Masiero A.
    Minerva Endocrinol; 2009 Dec 06; 34(4):333-8. PubMed ID: 20046162
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C.
    Ther Adv Cardiovasc Dis; 2008 Aug 06; 2(4):233-48. PubMed ID: 19124424
    [Abstract] [Full Text] [Related]

  • 39. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?
    Bangalore S, Kumar S, Messerli FH.
    Congest Heart Fail; 2013 Aug 06; 19(3):107-15. PubMed ID: 23241032
    [Abstract] [Full Text] [Related]

  • 40. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
    Rastogi A, Rashid M, Wright RF.
    J Clin Hypertens (Greenwich); 2011 Nov 06; 13(11):848-55. PubMed ID: 22051431
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.